Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review

Salciccia, Stefano; Frisenda, Marco; Bevilacqua, Giulio; Viscuso, Pietro; Casale, Paolo; Berardinis, Ettore De; Pierro, Giovanni Battista Di; Cattarino, Susanna; Giorgino, Gloria; Rosati, D; Giudice, Francesco Del; Sciarra, Alessandro; Mariotti, Gianna; Gentilucci, Alessandro

doi:10.1016/j.ajur.2023.01.002

Cited by 6 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the NLR has emerged as a novel indicator of inflammation across a spectrum of diseases, with several reports demonstrating its elevation in conditions such as prostate cancer [ 40 ], COVID-19 infection [ 41 ], and chronic obstructive pulmonary disease [ 42 ]. Furthermore, some scholars have extensively studied the application value of NLR in diabetes and its complications.…”

Section: Discussionmentioning

confidence: 99%

The association between the neutrophil-to-lymphocyte ratio and type 2 diabetes mellitus: a cross-sectional study

Chen,

Wu,

Cao

et al. 2024

BMC Endocr Disord

View full text Add to dashboard Cite

Background Type 2 diabetes mellitus (T2DM) is a prevalent chronic disease often accompanied by low-grade inflammation. Recently, the neutrophil-to-lymphocyte ratio (NLR) has garnered researchers’ interest as an emerging inflammation biomarker. This study aimed to comprehensively explore the relationship between NLR and T2DM using the National Health and Nutrition Examination Survey (NHANES) database. Method We employed a cross-sectional study design to analyze data from five NHANES cycles from 2007 to 2016, excluding individuals with incomplete data. This study utilized a weighted logistic regression model, subgroup analyses, and restricted cubic spline (RCS) analysis to assess the potential relationship between NLR and T2DM. Results A total of 9903 participants were eligible for the analysis, of which 1280 were diagnosed with T2DM. The T2DM group exhibited significantly higher NLR levels than the non-T2DM group. After adjusting for potential confounders, elevated NLR levels were associated with an increased risk of developing T2DM, indicated by an odds ratio (OR) of 1.14, 95% CI: (1.05,1.24), P = 0.003. The results of the subgroup analyses revealed a significant interaction effect between NLR and T2DM concerning race and hypertension (P for interaction < 0.05). In contrast, no significant interactions were found for age, sex, education level, body mass index (BMI), smoking status, recreational activities, and alcohol drinker (P for interaction > 0.05). RCS analysis showed a significant non-linear relationship between NLR and T2DM, with an inflection point at 2.27 (all P for non-linearity < 0.05). Conclusion Our study indicates that an elevated neutrophil-to-lymphocyte ratio is associated with a higher risk of T2DM.

show abstract

Section: Discussionmentioning

confidence: 99%

The association between the neutrophil-to-lymphocyte ratio and type 2 diabetes mellitus: a cross-sectional study

Chen,

Wu,

Cao

et al. 2024

BMC Endocr Disord

View full text Add to dashboard Cite

show abstract

“…Metaanalyses reported the independent predictor effects of NLR and PLR for survival similar to our study. [16,22] However, although there are studies in the literature investigating the predictive effect of MLR for diagnosis and recurrence in prostate cancer patients, there was no study investigating its prognostic significance in mCRPC patients. [23,24] In our study, which is the first report on the prognostic effect of MLR to the best of our knowledge, MLR was found to be the index with the highest prognostic power after NLR (HR: 2.53, 95% CI: 1.35–4.76, P = .004).…”

Section: Discussionmentioning

confidence: 99%

“…Although there are studies showing that it may be a prognostic biomarker in patients with mCRPC receiving chemotherapy, abiraterone, or radium-223, there is no data in the literature regarding the prognostic effect of inflammation indices in mCRPC patients receiving 177 Lu–PSMA-617 therapy. [15,16] In this study, it was aimed to evaluate the prognostic and predictive value of NLR, dNLR, PLR, MLR, SII, and PIV in mCRPC patients receiving 177 Lu–PSMA-617.…”

Section: Introductionmentioning

confidence: 99%

Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu–PSMA-617

Şahin,

Kefeli,

Zorlu

et al. 2023

Medicine

View full text Add to dashboard Cite

This study is aimed to investigate the prognostic significance of inflammation indices, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and pan-immune-inflammation value (PIV) in metastatic castration-resistant prostate cancer (mCRPC) patients who had received lutetium labeled prostate-specific membrane antigen (177Lu–PSMA-617) therapy. Sixty-one mCRPC patients who received 177Lu–PSMA-617 treatment and followed up in Kocaeli University were included. The relationship between overall survival (OS) and progression-free survival (PFS) and clinical and laboratory parameters was analyzed by multivariate analyses. The mean age was 69.8 ± 6.9 years. The mean follow-up time was 53.2 ± 24 months. The median OS was 14 (95% CI: 8.8–18.1) and the median PFS was 10.4 (95% CI: 4.7–17.2) months. NLR ≥ 2.7, PLR ≥ 134.27, SII ≥ 570.39, PIV ≥ 408.59 were considered as elevated levels. In the multivariate analysis for OS, baseline ECOG performance score (HR: 1.92, 95% CI: 1.01–3.65, P = .046), high albümin (HR: 0.36, 95% CI: 0.16–0.82, P = .015), primary resistant total prostate-specific-antigen (PSA) (HR: 4.37, 95% CI: 1.84–10.35, P = .001), high NLR (HR: 3.32, 95% CI: 1.66–6.65, P = .001), high MLR (HR: 2.53, 95% CI: 1.35–4.76, P = .004), high PLR (HR: 2.47, 95% CI: 1.23–4.96, P = .01), and high SII (HR: 2.17, 95% CI: 1.09–4.32, P = .027) were associated with shorter OS. However, PIV was not associated with survival (P = .69). No factor other than the primer-resistant PSA could be identified as having an impact on PFS (for the PSA, HR: 4.52, 95% CI: 1.89–10.76, P = .001). In this study, pretreatment NLR, MLR, PLR, and SII demonstrate as powerful independent prognostic indices predicting survival in patients with mCRPC receiving 177Lu–PSMA-617 therapy.

show abstract

“…Recently, immune inflammation indices such as neutrophil (N) to lymphocyte (L) ratio (NLR), platelet (P) to lymphocyte ratio (PLR), systemic immune inflammation index (SII = N x P / L) and combined LDH albumin score (CLAS) were investigated and found to be associated with decreased survival in some cancers. [7][8][9][10] CLAS is a scoring system first proposed by Daher et al in 2021 and includes four different prognostic groups : high LDH + low alb (CLAS 0), low LDH + low alb (CLAS 1), high LDH + high alb (CLAS 2), low LDH + high alb (CLAS 3). In this study, patients classified as CLAS 0 showed the lowest survival.…”

mentioning

confidence: 99%

Combined LDH Albumin Score (CLAS) and NeutrophilLymphocyte Ratio (NLR) are Predictive for Survival in Patients with Metastatic Non-Small Cell Carcinoma Treated with Nivolumab as Monotherapy

Sahin

2024

EJMI

View full text Add to dashboard Cite

L ung cancer is the most common cancer in men worldwide and the leading cause of cancer death (1.8 million deaths) in both sexes. [1] Lung cancer is classified into two main groups as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) according to the histology of the tumor. NSCLC is the most common (85-90%) group. [2] Without targetable mutation, 5-year survival is 50-82% in early-stage NSCLC and 6-10% in metastatic NSCLC (mNSCLC). [3] In the last decade, the 5-year survival in mNSCLC has increased to 24% due to the use of immunotherapies in the first series. [4] Nivolumab, one of the immune checkpoint inhibitors, inhibits PD-1 receptors and activates the immune system. In 2015, in patients with mNSCLC who progressed after platinum-based chemotherapy, Nivolumab demonstrated a median overall survival of 12.2 months versus 9.4 months. [5] In the first serial, it can be used in combination with ipi-Objectives: It was aimed to investigate the prognostic significance of neutrophil-to-lymphocyte ratio(NLR), plateletto-lymphocyte ratio(PLR), systemic immune-inflammation index(SII), and Combined LDH Albumine Score(CLAS) in metastatic non-small cell lung cancer(mNSCLC) patients receiving nivolumab. Methods: Sixty-five mNSCLC patients who received nivolumab as monotherapy and had a follow-up file in Kocaeli City Hospital were analyzed retrospectively. ROC-curve analysis and median values were used to determine the cut-off. The relationship between overall survival(OS), progression-free survival(PFS) and clinical and laboratory parameters was evaluated by multivariate analyses. Results: Mean age was 62.5±4.5 years, more than half(66%) had denovo metastatic disease. Median follow-up time was 22 (IQR:12-33),median PFS was 6 (95% CI 3.4-8.6),and median OS was 9 (95% CI 5.2-18.1) months. NLR≥3.2, PLR≥199, and SII≥776 were considered as elevated levels. No factor other than NLR could be identified as having an impact on PFS (p=0.015,[HR]:0.46,95%CI: 0.23-0.91). Univariate analyses showed that high baseline NLR, low baseline albumin and CLAS< 2 (0-1) were a significant risk factors for poor OS, but only CLAS<2 was found as an independent prognostic factor for OS in multivariate analyses (p=0.013,[HR]:0.68,95%CI:0.42-0,95). Conclusion: NLR and CLAS were predictive for survival in patients with NSCLC receiving nivolumab.This is the second study on CLAS in the literature.

show abstract

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review

Cited by 6 publications

References 49 publications

The association between the neutrophil-to-lymphocyte ratio and type 2 diabetes mellitus: a cross-sectional study

The association between the neutrophil-to-lymphocyte ratio and type 2 diabetes mellitus: a cross-sectional study

Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu–PSMA-617

Combined LDH Albumin Score (CLAS) and NeutrophilLymphocyte Ratio (NLR) are Predictive for Survival in Patients with Metastatic Non-Small Cell Carcinoma Treated with Nivolumab as Monotherapy

Contact Info

Product

Resources

About